EcoDrugPlus

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSMOCG00000003928
Gene Symbol: WEE1
3 Cross references
226 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSMOCG00000002556
Gene Symbol: YES1
3 Cross references
263 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSMOCG00000013374
Gene Symbol: ACHE
3 Cross references
233 Possible Orthologues:

Activin A Receptor Like Type 1

Ensembl ID : ENSMOCG00000006424
Gene Symbol: ACVRL1
3 Cross references
353 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSMOCG00000019420
Gene Symbol: ACVR2B
3 Cross references
257 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSMOCG00000017725
Gene Symbol: ADORA1
3 Cross references
269 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSMOCG00000017735
Gene Symbol: ADORA2A
3 Cross references
260 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSMOCG00000012952
Gene Symbol: ADORA2B
3 Cross references
200 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSMOCG00000018474
Gene Symbol: ADA
3 Cross references
216 Possible Orthologues:

Adenosine Receptor A3

Ensembl ID : ENSMOCG00000009194
Gene Symbol: LOC101987577
3 Cross references
89 Possible Orthologues:

Adhesion Regulating Molecule 1

Ensembl ID : ENSMOCG00000014522
Gene Symbol: ADRM1
2 Cross references
255 Possible Orthologues:

Adrenergic Receptor, Beta 3

Ensembl ID : ENSMOCG00000022956
Gene Symbol: ADRB3
1 Cross references
215 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).